fbpx

 Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia

LONDON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages

Read more

KBRA Credit Profile (KCP) K-LOC Index: September 2019

NEW YORK–(BUSINESS WIRE)–Kroll Bond Rating Agency (KBRA) releases its KBRA Credit Profile (KCP) K-LOC Index for the month of September. K-LOC Index The KBRA

Read more

Hal Keever Joins Atwell’s Portland Office

PORTLAND, Ore.–(BUSINESS WIRE)–Atwell, LLC is pleased to welcome Hal Keever as Vice President, Land Development. Keever will support Atwell’s land development operations with an

Read more

Hal Keever Joins Atwell’s Portland Office

PORTLAND, Ore.–(BUSINESS WIRE)–Atwell, LLC is pleased to welcome Hal Keever as Vice President, Land Development. Keever will support Atwell’s land development operations with an

Read more